Skip to main content
TCMD logo

TCMD · Tactile Systems Technology Inc

Track TCMD — free
$26.42 +0.37 (+1.42%) At close · Nov 18
Market Cap
$598.47M
Shares
22.65M
Volume · Nov 18 218.81K Avg daily vol (3M) 256.77K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$26.42 Open$26.34 Day$25.46–26.66 52W close$21.71–33.05 Avg vol 30d227K Short int2.8M · 12.3% of shares · 16.7d Short vol45% Last earningsNov 2, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 2

Up next

Feb 16, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Nov 3
Quarterly report 10-Q/A Ended Jun 30
Directors Adopt Pre-Arranged Stock-Sale Plans

Tactile Systems Technology, Inc. disclosed two directors’ pre-arranged stock-sale plans: William W. Burke adopted one on May 15, 2026 for up to 15,000 shares, and Laura G. King adopted one on May 18, 2026 for up to 6,000 shares.

5 source passages
Tactile Systems Technology, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, which was originally filed with the Securities and Exchange Commission (the “SEC”) on August 10, 2026 (the “Original Filing”). On May 15, 2026, William W. Burke, a member and Chairman of our Board of Directors, adopted a pre-arranged trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. This plan provides for the sale of up to 15,000 shares of our common stock in the aggregate and terminates on the earlier of the close of market on August 18, 2027, or the date all shares are sold thereunder. On May 18, 2026, Laura G. King, a member of our Board of Directors, adopted a pre-arranged trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. This plan provides for the sale of up to 6,000 shares of our common stock in the aggregate and terminates on the earlier of the close of market on December 31, 2026, or the date all shares are sold thereunder. Open the document at this passage
Nov 3
Quarterly report 10-Q/A Ended Sep 30
Amendment adds Rule 10b5-1 trading-plan disclosures

Tactile Systems Technology, Inc. added disclosures for Rule 10b5-1 plans adopted by William W. Burke and Kristie Burns during the quarter ended September 30, 2025, while making no changes to financial statements.

4 source passages
Tactile Systems Technology, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment”) to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, which was originally filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 (the “Original Filing”). On August 12, 2025, William W. Burke, a member and Chairman of our Board of Directors, adopted a pre-arranged trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. On September 11, 2025, Kristie Burns, then Senior Vice President, Marketing and Clinical Affairs of the Company, adopted a pre-arranged trading plan that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act. No changes have been made to the financial statements of the Company as contained in the Original Filing. Open the document at this passage
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month revenue rises 12%, net income grows 56%

Tactile Systems Technology reported nine-month revenue of $252.8 million, up 12% from $225.9 million, and net income of $13.2 million, up 56% from $8.5 million for the periods ended September 30, 2026 and 2025.

Revenue $91.86M ▲ 7.1% Net income $7.16M ▼ 12.8% Diluted EPS $0.31 ▼ 13.9%
Read from the MD&A section
3 source passages
Revenue increased $26.9 million, or 12%, to $252.8 million in the nine months ended September 30, 2026, compared to $225.9 million in the nine months ended September 30, 2025. For the nine months ended September 30, 2026, we generated revenue of $252.8 million and had net income of $13.2 million, compared to revenue of $225.9 million and net income of $8.5 million for the nine months ended September 30, 2025. Net income | | | $ | 13,182 | | | 5 | % | | $ | 8,452 | | | 4 | % | | $ | 4,730 | | | 56 | % Open the document at this passage
Nov 2
Current report 8-K
Revenue rose 7% as Adjusted EBITDA guidance increased

Tactile Systems Technology, Inc. reported third-quarter revenue up 7% to $91.9 million, while net income declined to $7.2 million. It raised full year 2026 Adjusted EBITDA guidance to $50 million to $52 million from $49 million to $51 million.

Financial results
4 source passages
Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2026. Total revenue in the third quarter of 2026 increased $6.1 million, or 7%, to $91.9 million, compared to $85.8 million in the third quarter of 2025. Net income in the third quarter of 2026 was $7.2 million, or $0.31 per diluted share, compared to $8.2 million, or $0.36 per diluted share, in the third quarter of 2025. The Company now expects full year 2026 Adjusted EBITDA in the range of $50 million to $52 million, compared to Adjusted EBITDA of $44.8 million in 2025. The Company’s prior 2026 Adjusted EBITDA guidance expectation was $49 million to $51 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$356.42M
Trailing 12 months
Net income (TTM)
$23.82M
Trailing 12 months
Revenue growth YoY
+7.1%
Year over year
Operating margin
9.4%
Trailing 12 months
P / E (TTM)
25.9
Trailing earnings · reciprocal yield 3.9%
FCF yield
4.8%
TTM · current market cap
Return on invested capital
14.6%
Trailing 12 months
Net cash
$75.11M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.4%
Year over year · more shares
Price change (1Y)
+13.9%
Trailing year
Short interest
12.3%
Latest settlement · 16.7 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26

TL;DR. Q2 revenue rose 9% to $85.7 million, gross margin expanded to 76.3%, net income increased 142% to $7.8 million, adjusted EBITDA increased 49% to $11.4 million, and lymphedema revenue rose 12%; the company launched next-generation AffloVest, secured MyoSleeve distribution rights, maintained $49 million to $51 million adjusted EBITDA guidance and expects low-double-digit lymphedema growth. AffloVest revenue fell 7%, Medicare prior authorization moderated Medicare orders, and the top end of 2026 revenue guidance declined from $368 million to $366 million amid DME inventory adjustments.

Bullish
  • + The company ended Q2 with $69.9 million in cash, no borrowings and $18.7 million remaining under its repurchase authorization.
  • + The company maintained its full-year 2026 adjusted EBITDA outlook of $49 million to $51 million.
  • + Six-month FlexiTouch head-and-neck trial results were published to support clinical adoption efforts.
  • + LymphaTech submitted an expanded diagnostic-aid indication for lymphedema with FDA-expected approval in 2027.
Bearish
  • − Q2 airway-clearance revenue decreased 7% to $12.1 million due to elevated inventory at several large DME partners.
  • − Q2 operating expenses increased 7% to $58.5 million as the company continued investing in growth initiatives.
  • − Commercial payer coverage changes are not expected to occur immediately after the head-and-neck publication.
  • − The Medicare prior-authorization requirement moderated Medicare order volumes during the quarter.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg +12%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 42%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +13%
trailing
6-month return +7%
trailing
YTD return −9%
this year
Relative strength +11%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $24 › 200d $26 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.31% of shares out · ▼ -1.5% MoM · 16.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
162 holders — mid 3-yr range
Squeeze score 84
high risk · 0–100
Fundamentals
Excellent
Revenue growth +12%
Y/Y
Gross margin 76%
expanding
EPS growth +17%
Y/Y
Free cash flow $40.4M
Valuation P/E 25.9
below peers
Buyback $12.5M
remaining
Balance sheet $83.4M
net cash
Quant / Vol
risk profile
High
Volatility 49%
annualized · 1-yr
Max drawdown −34%
past year
ATR 4.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Nov 2, 2026
Total revenue · full year 2026 Maintained $360M – $366M
Aug 10, 2026 $360M – $366M changed to Nov 2, 2026 $360M – $366M
prior FY $329.52M midpoint +10.2% Y/Y
Adjusted EBITDA · full year 2026 Non-GAAP Raised $50M – $52M
Aug 10, 2026 $49M – $51M changed to Nov 2, 2026 $50M – $52M
Previous outlook earlier release · from the Earnings Call filed May 4, 2026

Still-open targets the latest release did not restate under the same label.

GAAP gross margins · full year 2026 76% – 77%
GAAP operating expenses · full year 2026 10% – 12%
Guided vs delivered · last 4 settled
Total revenue full year 2025
guided $317M – $321M
$329.52M Beat +3.3%
Total revenue full-year 2022
guided $235M – $240M
$246.79M Beat +3.9%
Full year 2021 total revenue full year 2021
guided $203.5M – $206M
$208.06M Beat +1.6%
Total revenue full year 2020
guided $184.9M – $186.9M
$187.13M Beat +0.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
42% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $24 › 200d $26 — 200d above 50d
Institutional flow Distributing
-11% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.31% of shares out · ▼ -1.5% MoM · 16.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
162 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $22 Now $26 · 42% Range high $33
vs 200-day avg +3% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $15.1M six months ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TCMD
Tactile Systems Technology Inc
this stock
$598.47M -8.9% +12.5% 25.9 12.3%
ABT
Abbott Laboratories
$180.95B -16.6% +5.7% 39.0 1.1%
MDT
Medtronic plc
$128.83B +4.9% +8.4% 24.8 1.8%
SYK
Stryker Corp
$121.12B -9.5% +11.2% 33.9 1.7%
BSX
Boston Scientific Corp
$63.26B -54.2% +12.5% 18.5 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
162
% held
100.1%
Net QoQ
+768.6K sh
Top holder
CADIAN CAPITAL MANAGEMENT…
Held Float
View
Held by Funds
Fund positions
235
View
Short & Settlement
Short Interest Falling
Shares short
2.8M
Days to cover
16.7d
Change
-41.1K sh
View
Short Volume
Short vol %
45%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
5
Value
$122
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
35.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Tina Smith
Amount
$50.0K–$100.0K
Traded
Nov 12, 2024
View
Financials
Financials
Revenue (FY)
$329.5M
Net income (FY)
$19.1M
EPS diluted
$0.82
View
Buybacks
Authorized
$25.0M
Remaining
$12.5M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q/A
Filed
Nov 3, 2026
This year
18

Tactile Systems Technology, Inc. added disclosures for Rule 10b5-1 plans adopted by William W. Burke and Kristie Burns during the quarter ended September 30, 2025, while making no changes to financial statements.

View
Proposed Sales
Value
$120.0K
Shares
4.8K
Filed
Nov 3, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 2, 2026
View
Investor Relations
Latest news
Tactile Medical to Participate in…
Published
Nov 18, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
TCMD -2.6% +13.5% +7.4% +14.7% -8.9%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +1.3% +19.0% +10.8% +18.1% -16.0%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$25.00M
Spent (derived)
$12.50M
Remaining
$12.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1027838 CUSIP 87357P100 13F (30d) 174 filings 150 filers Visit website Investor relations